多发性硬化疾病修饰药物的研究新进展  

Recent advance in disease-modifying drugs for multiple sclerosis

作　　者：刘洋[1] 付锦[1] Liu Yang;Fu Jin(Department of Neurology,Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院神经内科,哈尔滨150086

出　　处：《中华神经医学杂志》2019年第12期1279-1283,共5页Chinese Journal of Neuromedicine

基　　金：国家自然科学基金(81171120)。

摘　　要：多发性硬化(MS)是一种中枢神经系统自身免疫性疾病,以白质脱髓鞘为主要特征,病程中反复复发缓解,在缓解期采用疾病修饰治疗,目标是降低复发和残疾进展风险。目前,已批准用于治疗MS的疾病修饰药物有皮下注射干扰素β和醋酸格拉替雷、小分子口服制剂(特立氟胺、富马酸二甲酯、芬戈莫德、克拉屈滨、西帕莫德)、静脉注射单克隆抗体(奥克雷珠单抗、阿仑单抗、那他珠单抗)以及化疗药物(米托蒽醌)等。本文将对MS的疾病修饰药物的研究新进展进行综述。Multiple sclerosis(MS)is an autoimmune disease of the central nervous system,mainly characterized by demyelination of white matter.It has been relapsed and remitted repeatedly during the course of the disease.In the remission period,it is treated with disease-modifying therapies.The goal is to reduce the risk of recurrence and disability progression.Until now,many disease-modifying drugs have been approved for MS,including subcutaneous injection of interferonβand glatiramer acetate,oral small molecule preparations(teriflunomide,dimethyl fumarate,fingolimod,cladribine,and siponimod),intravenous injection of monoclonal antibodies(ocrelizumab,alemtuzumab,and natalizumab)and chemotherapy drug(mitoxantrone).This article will review the recent advance in disease-modifying drugs for MS.

关 键 词：多发性硬化 疾病修饰药物 疾病修饰治疗 

分 类 号：R74[医药卫生—神经病学与精神病学]